Denosumab (anti-TNFSF11), 肿瘤坏死因子配体超家族成员 11 抑制剂

抗体

地诺单抗 | 迪诺苏单抗 | 地舒单抗 | TNFSF11抗体 | TNFSF11单克隆抗体 | TNFSF11药靶抗体 | RANKL抗体 | RANKL单克隆抗体 | RANKL药靶抗体 | CD254抗体 | CD254单克隆抗体 | CD254药靶抗体

Denosumab | AMG-162 | Prolia | Xgeva | Immunoglobulin G2 | Ranmark | CD254 antibody | hRANKL2 antibody | ODF antibody | OPGL antibody | OPTB2 antibody | Osteoclast differentiation factor antibody | Osteoprotegerin ligand antibody | Rank Ligand antibody |

Liquid

Ab169305-5mg

5mg

无动物源

≥95%(SDS-PAGE&SEC-HPLC)

>95%

-80℃储存,避免反复冻融

超低温冰袋运输

长期储存-20℃（24个月）；收货后建议分装，避免反复冻融。

Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0

No

Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.

ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)

CHO supernatant

人(Human)

人(Human), 食蟹猴(Cynomolgus monkey) | 人(Human),食蟹猴(Cynomolgus monkey)

RANKL

615258-40-7

26.6 kDa (Light Chain) & 51.2 kDa (Heavy Chain), under reducing conditions; 178.0 kDa, under non-reducing conditions.

Unconjugated

Human IgG1

重组抗体

kappa

Protein A purified

Primary antibody

抑制剂

肿瘤坏死因子配体超家族成员 11 抑制剂

Whole IgG